The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
Featured:
Paolo Ghia
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
In Arm D of the SEQUOIA trial, what was the highest rate of measurable residual disease negativity recorded?
A
B
C
D
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked about the latest update on the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
Listen to the podcast here:
SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL
In this interview, Paolo Ghia shares preliminary outcomes from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation, treated with zanubrutinib in combination with venetoclax. Ghia covers key data, highlighting promising remission rates and an increased depth of response measured over time. This interview concludes with a look to the future implications of these data, particularly on measurable residual disease-guided treatment cessation.
During the interview, Ghia made the following key points1:
- No new adverse events (AE) were observed, with the most common AE being diarrhea, neutropenia, and infections.
- The overall response rate was 100%.
- The complete remission rate was 48%.
- The highest rate of measurable residual disease negativity was 59%, recorded in the peripheral blood.
- At a median follow-up of 31.6 months, median progression-free survival (PFS) was not reached.
- The 12-month and 24-month estimated PFS rates were 95% and 94%, respectively.
Your opinion matters
As a result of this content, I commit to reviewing the latest data on zanubrutinib to guide my management of treatment-naïve patients with CLL/SLL.
This educational resource is independently supported by BeiGene. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
